INSULIN RESISTANCE, HYPERINSULINEMIA, AND DYSLIPIDEMIA IN NONOBESE INDIVIDUALS WITH A FAMILY HISTORY OF HYPERTENSION

被引:124
作者
FACCHINI, F [1 ]
CHEN, YDI [1 ]
CLINKINGBEARD, C [1 ]
JEPPESEN, J [1 ]
REAVEN, GM [1 ]
机构
[1] DEPT VET AFFAIRS MED CTR,CTR GERIATR RES EDUC & CLIN 182B,3801 MIRANDA AVE,PALO ALTO,CA 94304
关键词
FAMILY HISTORY OF HYPERTENSION; INSULIN RESISTANCE; HYPERINSULINEMIA; DYSLIPIDEMIA;
D O I
10.1093/ajh/5.10.694
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Various facets of glucose, insulin, and lipid metabolism were compared in 76 normal volunteers-38 with and 38 without a family history of hypertension. The two groups were comparable in terms of age, gender distribution, and degree of obesity (both generalized and abdominal). Although the plasma glucose response to oral glucose was similar in both groups, glucose-stimulated insulin concentrations were significantly greater in volunteers with a family history of hypertension (P < .001). Furthermore, the steady state plasma glucose concentration during a constant infusion of glucose, insulin and somatostatin was significantly greater in subjects with a family history of hypertension (8.1 +/- 0.6 v 6.2 +/- 0.6 mmol/L, P < .001). Since the steady-state plasma insulin levels during the infusion were similar, these results indicate that normotensive individuals with a family history of hypertension are relatively insulin resistant. Finally, plasma very low density lipoprotein (VLDL) triglyceride and VLDL cholesterol were higher in those with a family history of hypertension, as was the ratio of total to high density lipoprotein cholesterol. Thus, normotensive individuals with a family history of high blood pressure are insulin resistant, hyperinsulinemic and dyslipidemic when compared to a matched group of healthy volunteers without a family history of hypertension.
引用
收藏
页码:694 / 699
页数:6
相关论文
共 35 条
  • [1] Macmahon S.W., Cutler J.A., Furberg C.D., Et al., He effects of drug treatment of hypertension on morbidity and mortality from cardiovascular disease: A review of randomized controlled trials, Prog Cardiovasc Dis, 29, pp. 99-118, (1986)
  • [2] Collins R., Peto R., Macmahon S., Et al., Blood pressure, stroke, and coronary heart disease, Part 2. Short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context, Lancet, 335, pp. 827-838, (1990)
  • [3] Ames R.P., Metabolic disturbances increasing the risk of coronary heart disease during diuretic-based antihypertensive therapy: Lipid alterations and glucose intolerance, Am Heart J, 106, pp. 1207-1214, (1983)
  • [4] Leren P., Helgeland A., Holme I., Et al., Effect of propanolol and prazosin on blood lipids: The Oslo Study, The Lancet, 2, pp. 2-6, (1980)
  • [5] Weinberger M.H., Antihypertensive therapy and lipids: Paradoxical influences on cardiovascular disease risk, Am J Med, 80, pp. 64-70, (1986)
  • [6] Rohling J.J., Brunzell J.D., The effects of diuretics and adrenergic-blocking agents on plasma lipids, West J Med, 145, pp. 210-218, (1986)
  • [7] Lucas C.P., Estigarribia J.A., Darga L.L., Et al., Insulin and blood pressure in obesity, Hypertension, 7, pp. 702-706, (1985)
  • [8] Modan M., Halkin H., Almog S., Et al., Hyperinsulinemia: A link between hypertension, obesity and glucose intolerance, J Clin Invest, 75, pp. 809-817, (1985)
  • [9] Ferrannini E., Buzzigoli G., Bonadona R., Insulin resistance in essential hypertension, N Engl J Med, 317, pp. 350-357, (1987)
  • [10] Fuh M.-T., Shieh S.M., Wu D.-A., Et al., Abnormalities of carbohydrate and lipid metabolism in patients with hypertension, Arch Intern Med, 147, pp. 1035-1038, (1987)